利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

35 records (took 0.029 seconds)

    ORGAN PRESERVATION SOLUTION
    3.
    发明申请
    ORGAN PRESERVATION SOLUTION 审中-公开

    公开(公告)号：US20170202210A1

    公开(公告)日：2017-07-20

    申请号：US15312675

    申请日：2015-02-24

    Applicant: SBI Pharmaceuticals Co., Ltd. ,  National Center for Child Health and Development

    Inventor： Tohru TANAKA ,  Motowo NAKAJIMA ,  Urara OTA ,  Hidenori ITO ,  Ko RII

    IPC: A01N1/02

    CPC classification number: A01N1/0226 ,  A01N1/02

    Abstract: Provided is an organ preservation solution for use in transplantation, which is capable of effectively preventing the occurrence of ischemia-reperfusion injury. Prepared is an organ preservation solution comprising a mixture of the following components: (a) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, and D-glucose; (b) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, glycine, and D-glucose; (c) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, L-cysteine, glycine, and D-glucose; or (d) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, L-cysteine, glycine, an iron compound, and D-glucose.

    Immune tolerance inducer
    9.
    发明授权
    Immune tolerance inducer 有权
    免疫耐受诱导物

    公开(公告)号：US09399029B2

    公开(公告)日：2016-07-26

    申请号：US14413151

    申请日：2013-07-03

    Applicant: SBI PHARMACEUTICALS CO., LTD. ,  National Center for Child Health and Development

    Inventor： Tohru Tanaka ,  Motowo Nakajima ,  Fuminori Abe ,  Naomi Haga ,  Kiwamu Takahashi ,  Hidenori Ito ,  Ko Rii

    IPC: A61K31/197 ,  A61K33/26 ,  C12N5/0784 ,  A61K38/19 ,  A61K31/194 ,  A61K38/40

    CPC classification number: A61K31/197 ,  A61K31/194 ,  A61K33/26 ,  A61K38/193 ,  A61K38/40 ,  C12N5/064 ,  C12N2500/24 ,  C12N2501/052 ,  C12N2501/22 ,  C12N2501/2304 ,  A61K2300/00

    Abstract: An object of the present invention is to provide a regulatory dendritic cell inducing agent applicable to the treatment of immune disease as well as an immune tolerance inducing agent such as a preventive and/or therapeutic agent for allergic disease and a preventive and/or therapeutic agent for autoimmune disease, both of which are safe and have the mechanism of action different from that of conventional drugs. As a means for achieving the above object, an immune tolerance inducing agent comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-ALA or the derivative and an iron compound as active ingredients is prepared. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.

    Abstract translation: 本发明的目的是提供适用于免疫疾病的治疗的调节性树突状细胞诱导剂以及免疫耐受诱导剂，例如过敏性疾病的预防和/或治疗剂以及预防和/或治疗剂 对于自身免疫性疾病，两者都是安全的，并且具有与常规药物不同的作用机制。 作为实现上述目的的方法，制备包含5-氨基乙酰丙酸（ALA）或其衍生物或5-ALA或其衍生物和铁化合物的盐作为活性成分的免疫耐受诱导剂。 ALA的优选实例可以包括ALA和各种酯，例如ALA的甲酯，乙酯，丙酯，丁酯和戊酯，以及它们的盐酸盐，磷酸盐和硫酸盐。 铁化合物的优选实例可包括柠檬酸亚铁钠。

    DNA CONTROLLING MIR-140 EXPRESSION, AND SCREENING METHOD OF DRUGS USING SAID DNA
    10.
    发明申请
    DNA CONTROLLING MIR-140 EXPRESSION, AND SCREENING METHOD OF DRUGS USING SAID DNA 有权
    控制MIR-140表达的DNA，以及使用合成DNA的药物筛选方法

    公开(公告)号：US20150056630A1

    公开(公告)日：2015-02-26

    申请号：US14388609

    申请日：2013-04-02

    Applicant: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT ,  NIPPON ZOKI PHARMACEUTICAL CO., LTD.

    Inventor： Hiroshi Asahara ,  Satoshi Yamashita ,  Mitsuru Naiki ,  Kentaro Abe

    IPC: G01N33/53 ,  C12N15/113

    CPC classification number: G01N33/5308 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/03 ,  C12N15/113 ,  C12N2310/141 ,  G01N2400/10 ,  G01N2500/02 ,  G01N2500/04 ,  G01N2500/10

    Abstract: An object of the present invention is to provide DNA which regulates the expression of miR-140, a reporter vector which contains the DNA, cells and animals into which the reporter vector is introduced and a screening system for drugs which control the expression of miR-140 and is also to contribute in the development of new therapeutic agents for cartilage diseases such as osteoarthritis and intervertebral disk degeneration using the screening system. The DNA sequence according to the present invention is able to express any gene in a site where miR-140 is expressed and, in addition, it is also able to be utilized for screening a drug which regulates the expression of miR-140. Moreover, the drug that is selected by the screening system of the present invention is expected as a therapeutic agent for cartilage diseases accompanied by abnormality of cartilage.

    Abstract translation: 本发明的目的是提供调节miR-140表达的DNA，该载体包含引入报道载体的DNA，细胞和动物以及控制miR-140表达的药物的筛选系统， 并且还利用筛选系统为软骨疾病如骨关节炎和椎间盘退变的新治疗剂的开发作出贡献。 根据本发明的DNA序列能够在miR-140表达的位点中表达任何基因，此外，它还能够用于筛选调节miR-140表达的药物。 此外，预期本发明的筛选系统选择的药物是软骨异常伴随软骨疾病的治疗剂。

Patent Agency Ranking